Cannformatics, founded with a mission to improve health and quality of life through science-based outcomes, is a biotechnology company specializing in the development of saliva-based Cannabis-Responsive™ biomarkers. Their core vision is to deliver predictable and repeatable results in medical cannabis treatments. Cannformatics focuses on leveraging these biomarkers to personalize medical cannabis treatments, particularly for conditions such as autism spectrum disorder (ASD).
Notable achievements include the publication of groundbreaking research in "Scientific Reports," highlighting their progress in personalizing medical cannabis treatments for children with ASD using machine learning approaches. The company has garnered attention for its innovative approach and potential impact on the medical cannabis industry. Key affiliated individuals and investors have not been specified, but the company's advancements position it as a significant player in the intersection of biotechnology and medical cannabis.
